Abstract | BACKGROUND: AIM: To compare the efficacy of dosing ranitidine 75 mg or placebo 30 min prior to a proven heartburn-provoking meal in completely preventing or reducing subsequent heartburn symptoms. METHODS: A randomized, double-blind, parallel methodology was used at nine investigative centres. Following a screening visit, patients ate a standard test meal consisting of chili, chips and a soft drink on two occasions. On the first occasion, patients received single-blind placebo 30 min before the meal. This meal was used to qualify patients and to ensure the onset of a minimum level of heartburn. Patients who qualified were randomized (n = 284) to receive double-blind ranitidine 75 mg or placebo 30 min before a second test meal administered 4-14 days later at the treatment visit. Patients recorded whether heartburn was present and rated heartburn severity by completing visual analogue scales at 15-min intervals over the 4. 5 h meal evaluation periods. RESULTS: Statistically significant differences favouring ranitidine 75 mg were determined for complete prevention of heartburn (P < 0.006), heartburn severity area under the curve (P < 0.001), a clinical success end-point (P < 0.001), and all other end-points (P < 0.001). CONCLUSIONS: These data clearly demonstrate that ranitidine 75 mg is effective in completely preventing or decreasing heartburn when administered 30 min prior to a provocative meal.
|
Authors | K A Pappa, B O Williams, J E Payne, K S Buaron, K L Mussari, A A Ciociola |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 13
Issue 4
Pg. 467-73
(Apr 1999)
ISSN: 0269-2813 [Print] England |
PMID | 10215730
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Ulcer Agents
- Nonprescription Drugs
- Ranitidine
|
Topics |
- Adult
- Anti-Ulcer Agents
(administration & dosage, adverse effects, therapeutic use)
- Double-Blind Method
- Female
- Food
(adverse effects)
- Heartburn
(prevention & control)
- Humans
- Male
- Nonprescription Drugs
- Ranitidine
(administration & dosage, adverse effects, therapeutic use)
- Treatment Outcome
|